Atossa Therapeutics (ATOS) Analyst & Key Data

Analyst Consensus

Buy1 analysts

Buy

Updated Sep 12, 2026

Total Analysts1

Buy

4

Hold

1

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score5.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score4.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$2.51

Median Target+298.41%

$10.00

Potential upside vs current price

DCF Value+73.14%

$4.35

Potential upside vs current price

Current Stock Price

$2.51

Median Target+298.41%

$10.00

Potential upside vs current price

DCF Value+73.14%

$4.35

Potential upside vs current price

Analyst Consensus

Buy1 analysts

Buy

Updated Sep 12, 2026

Total Analysts1

Buy

4

Hold

1

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score5.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score4.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$2.51

Median Target+298.41%

$10.00

Potential upside vs current price

DCF Value+73.14%

$4.35

Potential upside vs current price

Current Stock Price

$2.51

Median Target+298.41%

$10.00

Potential upside vs current price

DCF Value+73.14%

$4.35

Potential upside vs current price

Atossa Therapeutics, Inc.